advanced melanomastage III/IV unresectable melanomaPembrolizumabNCT05309421
…aluated in combination with Pembrolizumab in a phase 2 trial in advanced melanoma ( NCT05309421), with 80% of the vaccine targets eliciting T-cel…
1articles mentioning diseases
1disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
Active filtersEntity: stage III/IV unresectable melanoma ×
stage III/IV unresectable melanoma
This disease is selected. Its supporting articles are shown below.